Candel Therapeutics 80.4 percent of patients achieve complete response in phase 3 prostate cancer trial

Candel Therapeutics 80.4 percent of patients achieve complete response in phase 3 prostate cancer trial
Candel Therapeutics posts trial result

Candel Therapeutics, Inc. announced the publication of its pivotal phase 3 trial results for aglatimagene besadenovec (CAN-2409) in The Lancet Oncology. In the study focusing on localized prostate cancer, 80.4 percent of treated patients achieved a pathological complete response in two-year biopsies, compared to 63.6 percent for those on placebo.

These results highlight substantial progress in prostate cancer research, positioning aglatimagene besadenovec as a potential new treatment option. The findings could have significant implications for future prostate cancer therapies. Shares of Candel Therapeutics trade under the ticker $CADL.

Earlier this year, Candel Therapeutics CEO called for prioritizing patient engagement to accelerate drug discovery at BioEquityEurope. The company’s regulatory leadership was also recognized when Chief Regulatory Officer Susan Stewart was named among the RAPSorg 50 for 50 for regulatory excellence. These initiatives reflect Candel’s ongoing focus on innovation and regulatory standards.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.